the aid library

LIST OPTIONS

Filter

5333

COVID-19: Exercise du simulation sur table (TTX) - Guide du Facilitateur

World Health Organisation (WHO) Health Emergencies Programme (2020) C_WHO

L'exercice de table COVID-19 (TTX) est un package de simulation qui utilise un scénario progressif ainsi qu'une série d'injects spécifiques pour permettre aux participants de considérer l'impact potentiel d'une épidémie sur les plans, procédures et capacités existants. Le TTX a pour objectif... more

COVID-19: Exercice de simulation sur table (TTX) - Guide du participant

World Health Organisation (WHO) Health Emergencies Programme (2020) C_WHO

L’exercice COVID-19 de Table Top (TTX) est un outil qui a été développé pour aider les gouvernements et les organismes à renforcer les plans et les politiques dans le but d’identifier, de contenir l’apparation de cas de COVID-19 dans le pays. La simulation TTX est conçue pour soutenir l�... more

Download (154)

View PDF (184)

COVID-19: Health Emergency Preparedness Table-Top Exercise (TTX) - Participant's Guide

World health Organisation (WHO) Health Emergencies Programme (2020) C_WHO

The Table Top (TTX) COVID-19 exercise is a tool that has been developed to assist Governments and Agencies in the process of strengthening plans and policies with the intention of being able to identify and contain and outbreak of COVID19 in the country. The TTX Simulation is designed to support the... more

Download (242)

View PDF (177)

COVID-19: IPC Simulation Exercise

World Health Organisation (WHO) Health Emergencies Programme (2020) C_WHO

General Objectives 1. Share information on practices on IPC for endemic colonization in a tertiary facility and how those precautions could evolve based on the progress of the event, then further integrating response capabilities, plans and procedures to triage and implement source control measure... more

Download (118)

View PDF (143)

ИМИТАЦИОННЫЕ УЧЕНИЯ ПО ОБЕСПЕЧЕНИЮ ГОТОВНОСТИ К ЧРЕЗВЫЧАЙНОЙ СИТУАЦИИ В ОБЛАСТИ ОБЩЕСТВЕННОГО ЗДРАВООХРАНЕНИЯ

Wolrd Health Organisation (WHO) Health Emergencies Programme (2020) C_WHO

Общие цели 1. Распространить информацию о ходе подготовки, в том числе о потенциале в области реагирования и планах и процедурах реагирования в целях выявления за�... more

Download (156)

View PDF (169)

Стандартные меры предосторожности в здравоохранении

Всемирная организация здравоохранения (ВОЗ) (2007) C_WHO

ОКТЯБРЬ 2007 г. ИНФЕКЦИОННЫЙ КОНТРОЛЬ Стандартные меры предосторожности предназначены для снижения риска передачи переносимых с кровью и других возбудителей как ... more

Download (101)

View PDF (141)

Выдача иммунных паспортов в контексте COVID-19

Всемирная организация здравоохранения (ВОЗ) (2020) C_WHO

Научная справка 24 апреля 2020 г. При инфицировании в естественных условиях выработка иммунитета к патогенному микроорганизму проходит в несколько этапов и заним�... more

Download (109)

View PDF (174)

Viruses or Bacteria: What’s got you sick?

CDC Centers for Disease Control and Prevention (2019) C_CDC

Antibiotics are only needed for treating certain infections caused by bacteria. Viral illnesses cannot be treated with antibiotics. When an antibiotic is not prescribed, ask your healthcare professional for tips on how to relieve symptoms and feel b... more

COVID Reference 2021.6 EN
recommended

Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC

Download (2590)

View PDF (1546)

Rwanda: GYNECOLOGY AND OBSTETRICS CLINICAL PROTOCOLS & TREATMENT GUIDELINES

Ministry of Health, Rwanda (2012) C2

The guidelines presented in this document are designed to provide a useful resource for healthcare professionals involved in clinical case management. They were developed taking into consideration services provided at different levels within the health system and resources available. These guideline... more

External Link

Elementos de protección personal UCI - Covid-19

AMCI Association Colombiana de Medicina Critica y Cuidado Intensivo (2020) CC

Marburg virus disease (MVD)

Internation Federation of Red Cross (2022) CC2

Hey Facts about the disease

External Link (198)

Marburg Virus: reducing the risk of transmission

European Centre for Disease Prevention and Control (ecdc) (2024) C_CDC

Infographic

Guidelindes for prevention of Marburg virus disease

Republic of Rwanda-Ministry of Health (2024) CC

Prevention Guidelines on Marburg virus disease

External Link (194)

Lessons Learnt from the Marburg Virus Disease (MVD) Outbreak in Tanzania

Africa CDC (2023) C_CDC

On March 16, 2023, the Tanzania Ministry of Health declared an outbreak of an unidentified illness in Bukoba district, Kagera region. A group of seven individuals presented with fever, vomiting, bleeding from various body orifices, and kidney failure, sparking suspicion of a contagious disease. Labo... more

External Link

Posters and Factsheets Ebola Virus Disease

Centers for Disease Control and Prevention CDC (2022) CC

Poster for communities and health worker

Download (318)

View PDF (298)

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the ... from animals to humans. Mpox is a viral illness caused by the monkeypox virus (MPXV). It can cause a painful rash, enlarged lymph nodes and fever. Most people fully recover, but some get very sick. The virus transmits from person to person through close, including sexual, contact. It also has animal reservoirs in east, central and west Africa, where spillovers from animals to humans can occasionally occur, sparking further outbreaks. There are two different clades of the virus: clade I and clade II. Clade I outbreaks are deadlier than clade II outbreaks. A major emergence of mpox linked to clade II began in 2017, and since 2022, has spread to all regions of the world. Between July 2022 and May 2023, the outbreak was declared a Public Health Emergency of International Concern. While that outbreak has largely subsided, cases and deaths continue to be reported today, illustrating that low-level transmission continues around the world. Currently, there is also a major outbreak of clade I virus in the Democratic Republic of the Congo (DRC), where cases have been on the rise for decades. Since the beginning of the year, over 6500 cases and 345 deaths have been reported in the DRC. Almost half of these are among children under the age of 15 years. The Strategic framework for enhancing prevention and control of mpox (2024–2027) provides a roadmap for health authorities, communities, and stakeholders worldwide to control mpox outbreaks in every context, advance mpox research and access to countermeasures, and to minimize zoonotic transmission. more

Mpox Outbreak Toolbox, Updated: January 2023

World Health Organization WHO; Health Cluster (2024) CC

i. A person who is a contact of a probable or confirmed mpox case in the 21 days before the onset of signs or symptoms, and who presents with any of the following: acute onset of fever (>38.5°C), headache, myalgia (muscle pain/body aches), back pain, profound weakness or fatigue. OR ii. A per... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

COVID Reference 2021.6 EN recommended

COVID Reference 2021.6 EN
recommended